MAPK

Items 1-50 of 216

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. Raf inhibitor

    Sorafenib Tosylate (Nexavar) is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.
  2. Raf inhibitor

    PLX-4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
  3. MEK1/2 inhibitor

    AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor that inhibits growth and survival of MM cells and cytokine-induced osteoclast differentiation.
  4. Anti-inflammatory agent

    Asiatic acid is commonly used in wound healing. Asiatic acid has antioxidant, anti-inflammatory and neuroprotective properties. Asiatic acid derivative synthesis can be used as Anticancer agents; Glycogen phosphorylase inhibitors; Hepatoprotectants.

  5. MEK Inhibitor

    AZD8330 is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. Phase 1.
  6. p38 MAPK inhibitor

    Doramapimod (BIRB 796) is a small molecule inhibitor of p38 MAPK,which plays a critical role in regulating the production of proinflammatory cytokines.
  7. MEK5 inhibitor

    BIX02188 is a potent and selective inhibitor of MEK5.
  8. MEK inhibitor

    BIX 02189 is a selective dual MEK5 and ERK5 (or BMK1) kinase inhibitor, with IC50 values of 1.5, 59, 580 and >6200 nM for MEK5, ERK5, TGFbR1 and other closely related kinases respectively.
  9. MEK1/2 inhibitor

    PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
  10. VEGFR inhibitor

    Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
  11. MEK inhibitor

    PD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
  12. MEK inhibitor

    AZD6244 (Selumetinib) also known as Selumetinib, ARRY142886, AZD-6244 & ARRY-142886 is MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nm.
  13. B-Raf inhibitor

    GDC-0879 is a specific inhibitor of B-Raf kinase enzyme,targeting B-Raf (V600E) (IC50: 0.13 nM).
  14. Antiangiogenic and Antitumor Agent

    Honokiol is a lignan present in the cones, bark, and leaves of Magnolia grandiflora that has shown pro-apoptotic effects in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate, oral squamous cell carcinoma and colon cancer cell lines.
  15. p38 MAPK inhibitor

    LY2228820 is a novel and potent p38MAPK inhibitor with potent antiinflammatory activity.
  16. EphB4 inhibitor

    NVP-BHG712 is a selective inhibitor of EphB4 kinase that exhibits selectivity for EphB4 over more than 40 other kinases in vitro, including FGFR3.
  17. MEK Inhibitor

    PD318088 is an inhibitor of MEK1 AND MEK2.
  18. MEK Inhibitor

    PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase.
  19. Raf inhibitor

    PLX4032 (Vemurafenib) also known as RG7204, Vemurafenib, R7204; RO5185426. PLX4032 is a B-raf inhibitor with an IC50 of 44 nM.
  20. RAF/VEGFR Inhibitor

    RAF265 (CHIR-265) is an oral, highly selective RAF and VEGFR kinase inhibitor, which is to control or normalize VEGFR-2 along with the inhibition of B-raf and c-Raf mutation to prevent cancers.
  21. RAF/VEGFR Inhibitor

    Raf265 derivative is a derivative of Raf265 that is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM.
  22. p38 MAPK Inhibitor

    SB202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase.
  23. p38 MAPK inhibitor

    SB 203580 is a specific inhibitor of p38α and p38β which suppresses downstream activation of MAPKAP kinase-2 and heat shock protein 27.
  24. B-Raf Inhibitor

    SB590885 is a selective small-molecule inhibitor of the B-Raf kinase and Ki app values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively.
  25. JNK inhibitor

    SP600125 is a JNK inhibitor with IC50=40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3.
  26. p38 MAPK inhibitor

    Pexmetinib is a potent inhibitor of cytokine synthesis, via the dual inhibition of p38 mitogen-activated protein kinase (MAPK), and Tie2/Tek receptor tyrosine kinase.
  27. MEK inhibitor

    U0126-EtOH is an inhibitor of both MEK1 and MEK2 with an IC50 of 72 nM and 58 nM respectively.
  28. p38 MAPK inhibitor

    AMG 548 is a potent and selective inhibitor of p38α. It displays >1000-fold selectivity against 36 other kinases, and it inhibits whole blood LPS-stimulated TNFα.
  29. p38 MAPK inhibitor

    VX-702 is an orally bioavailable inhibitor of p38 MAP kinase that inhibits platelet agonist induced p38 activation (IC50= 4 to 20 nM).
  30. p38 MAPK inhibitor

    VX-745 is a small-molecule inhibitor of MAPK that is reported to be active against several isotypes of p38 MAPK, including p38α, p38βand p38γ .
  31. MEK Inhibitor

    GSK1120212 (JTP-74057) strongly prevented the activities of MEK1 and MEK2 kinases rather than activities of other 98 kinases.
  32. MEK Inhibitor

    TAK-733 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity.
  33. Raf inhibitor

    AZ628 is a RAF inhibitor with IC50 values: ca 30 nM for BRAF V600E and wild-type CRAF and 100 nM for wild-type BRAF.
  34. C-Raf inhibitor

    ZM 336372 is a potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells.
  35. p38 MAPK inhibitor

    PH-797804 is a diarylpyridinone inhibitor of p38 mitogen-activated protein (MAP) kinase.
  36. p38 MAPK inhibitor

    SKF 86002 Dihydrochloride is inhibitor of p38 MAP kinase (IC50 = 0.1 - 1 uM). Potently inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50 = 1 uM).
  37. Raf inhibitor

    ML 786 dihydrochloride is a potent Raf kinase inhibitor (IC50 values are 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf respectively).
  38. p38 MAPK inhibitor

    PD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
  39. ERK1/RasGAP Inhibitor

    The activity of Pluripotin (SC-1) is mediated by the combined inhibition of RasGAP and ERK1 with Kd values of 98 and 212 nM, respectively.
  40. pan-Raf inhibitor

    MLN 2480 is an oral, selective pan-Raf kinase inhibitor in chinical trials.
  41. MEK1/2 inhibitor

    RO4927350 a potent and highly selective non-ATP-competitive MEK1/2 inhibitor.
  42. MEK inhibitor

    Refametinib is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
  43. SAPKs/JNKs activator

    Anisomycin is a pyrrolidine antibiotic, acts as an anti-fungal antibiotic which inhibits Protein Synthesis, also is a potent activator of SAPKs/JNKs.
  44. JNK inhibitor

    AEG 3482 is a small-molecule inhibitor of Jun kinase (JNK)-dependent apoptosis.
  45. JNK inhibitor

    AS 602801 is a novel, orally active, Jun Kinase Inhibitor.
  46. p38 MAPK inhibitor

    Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor.
  47. BRAF inhibitor

    BRAF inhibitor is a potent BRAF inhibitor.
  48. JNK inhibitor

    CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
  49. Raf inhibitor

    Dabrafenib is a potent and selective inhibitor of B-RAF protein kinase carrying V600E mutation, currently in clinical trial.
  50. Raf-1 Inhibitor

    GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor

Items 1-50 of 216

Page
per page
Set Descending Direction